Nisa Investment Advisors LLC decreased its stake in Humana Inc. (NYSE:HUM) by 2.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,279 shares of the insurance provider’s stock after selling 900 shares during the period. Nisa Investment Advisors LLC’s holdings in Humana were worth $6,771,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of HUM. Point72 Asia Hong Kong Ltd purchased a new stake in Humana during the second quarter valued at about $126,000. Daiwa SB Investments Ltd. raised its stake in Humana by 1.4% in the third quarter. Daiwa SB Investments Ltd. now owns 730 shares of the insurance provider’s stock valued at $129,000 after buying an additional 10 shares during the last quarter. Bessemer Group Inc. raised its stake in Humana by 14.0% in the second quarter. Bessemer Group Inc. now owns 1,140 shares of the insurance provider’s stock valued at $205,000 after buying an additional 140 shares during the last quarter. Fulton Bank N.A. purchased a new stake in Humana during the third quarter valued at about $229,000. Finally, BB&T Securities LLC raised its stake in Humana by 13.6% in the second quarter. BB&T Securities LLC now owns 1,374 shares of the insurance provider’s stock valued at $247,000 after buying an additional 165 shares during the last quarter. 91.71% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Humana Inc. (NYSE:HUM) traded up 0.51% during mid-day trading on Wednesday, reaching $211.08. 1,102,740 shares of the company traded hands. The stock has a market capitalization of $31.47 billion, a PE ratio of 28.54 and a beta of 0.80. The stock has a 50-day moving average of $182.87 and a 200 day moving average of $177.74. Humana Inc. has a 52-week low of $150.00 and a 52-week high of $211.49.

Humana (NYSE:HUM) last released its quarterly earnings data on Friday, November 4th. The insurance provider reported $3.18 EPS for the quarter, topping analysts’ consensus estimates of $3.09 by $0.09. The firm had revenue of $13.69 billion for the quarter, compared to the consensus estimate of $13.41 billion. Humana had a net margin of 2.00% and a return on equity of 12.32%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.16 earnings per share. Equities research analysts expect that Humana Inc. will post $9.51 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Thursday, January 12th will be issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date of this dividend is Tuesday, January 10th. Humana’s dividend payout ratio is currently 15.96%.

TRADEMARK VIOLATION WARNING: “Humana Inc. (HUM) Stake Decreased by Nisa Investment Advisors LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international trademark and copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/30/humana-inc-hum-stake-decreased-by-nisa-investment-advisors-llc.html.

HUM has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $198.00 target price on the stock in a research note on Tuesday, October 4th. Evercore ISI started coverage on shares of Humana in a research note on Thursday, September 22nd. They issued a “buy” rating and a $200.00 price target on the stock. Jefferies Group reaffirmed a “buy” rating and issued a $206.00 price target on shares of Humana in a research note on Monday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Humana in a research note on Monday, August 8th. Finally, Barclays PLC decreased their price target on shares of Humana from $193.00 to $191.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 4th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Humana currently has a consensus rating of “Buy” and an average target price of $205.00.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

5 Day Chart for NYSE:HUM

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.